Abstract
Oral hypoglycemic agents have been in clinical use since 1956 in the United States. Two new second-generation sulfonylureas, glipizide and glyburide, have been marketed recently. This article reviews the pharmacology of the oral sulfonylureas, compares the drugs from a safety and efficacy standpoint, and provides updated information regarding their use in the management of type II non-insulin-dependent diabetes mellitus.
MeSH terms
-
Administration, Oral
-
Chlorpropamide / adverse effects
-
Diabetes Mellitus, Type 2 / drug therapy*
-
Drug Hypersensitivity / etiology
-
Glipizide / administration & dosage
-
Glipizide / metabolism
-
Glipizide / therapeutic use
-
Glyburide / administration & dosage
-
Glyburide / metabolism
-
Glyburide / therapeutic use
-
Humans
-
Insulin Resistance
-
Kinetics
-
Liver / metabolism
-
Nausea / chemically induced
-
Patient Education as Topic
-
Sulfonylurea Compounds / administration & dosage
-
Sulfonylurea Compounds / metabolism
-
Sulfonylurea Compounds / therapeutic use*
Substances
-
Sulfonylurea Compounds
-
Glyburide
-
Chlorpropamide
-
Glipizide